Cooperative Agreement U01GH002386

This Project Grant award of $133,203 was provided by the National Science Foundation (NSF) through its Mathematical and Physical Sciences (CFDA 47.049) program. The award supports a collaborative research project among the University of Florida, University of Georgia, and University of Massachusetts Amherst to develop advanced mathematical models to improve understanding and management of schistosomiasis transmission dynamics, with a focus on the transition from high to low transmission phases...

The University of New Mexico received a $430,251 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct genetic mapping research on advanced intercross lines of the Biomphalaria glabrata snail, a vector for the schistosomiasis parasite. The research aims to identify genomic regions and genes that regulate schistosome resistance and per capita cercarial production in these snails, with the goal of...

This $196,163 federal Project Grant award from the National Science Foundation (NSF) under the Mathematical and Physical Sciences program (CFDA 47.049) is funding a collaborative research project on developing advanced mathematical models to improve understanding and management of schistosomiasis transmission dynamics. The project is a collaboration between the University of Florida, University of Georgia, and University of Massachusetts, and aims to create innovative hybrid...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $810,158 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop a novel antischistosomal compound to treat human schistosomiasis, a disease that affects over 200 million people globally. The research aims to optimize an oxamniquine (OXA) derivative that has shown broad activity against the...

This Project Grant award from the John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $108,237 to Mbarara University of Science and Technology in Uganda to develop and assess the feasibility of a diagnostic tool for post-tuberculosis (TB) lung disease that can be deployed in primary healthcare settings. The key objectives are to: (1) create and validate a clinical diagnostic algorithm for post-TB lung disease, (2) conduct qualitative...

This federal Project Grant award in the amount of $746,813.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to increase appropriate treatment of Shigella while limiting antimicrobial resistance in low-resource settings. The key objectives are to: 1) characterize the impact of inappropriately treated Shigella on diarrhea outcomes in children in Tanzania, 2) evaluate novel...

This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $155,686 to Baylor College of Medicine to conduct a prospective study evaluating diagnostic strategies for strongyloidiasis, a parasitic infection caused by Strongyloides stercoralis. The study aims to (1) identify high-performing screening methods for at-risk U.S. populations and (2) evaluate assays as tests-of-cure. The project period runs...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,204 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the London School of Hygiene and Tropical Medicine (LSHTM) to conduct research on complex malaria in India. The key products and services to be delivered through this 5-year project include: Monitoring the changing epidemiology of malaria in Odisha, India through a 4-year community-based cohort study to...

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,857,470 Cooperative Agreement to The Geneva Foundation to develop a multiplex testing platform that can simultaneously detect and identify Plasmodium species infections. This platform will serve as both a diagnostic tool and an epidemiological surveillance tool. The project performance period is from June 1, 2024 to May 31, 2028. Under a $268,312 sub-award, Meso Scale...